Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock

Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.

While analyzing BIO's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.

For the quarter, the company's total revenue amounted to $651 million, experiencing a decline of 0.1% year over year. Next, we'll explore the breakdown of BIO's international revenue to understand the importance of its overseas business operations.

Decoding BIO's International Revenue Trends

Asia generated $121.8 million in revenues for the company in the last quarter, constituting 18.7% of the total. This represented a surprise of -10.74% compared to the $136.46 million projected by Wall Street analysts. Comparatively, in the previous quarter, Asia accounted for $110.4 million (18.7%), and in the year-ago quarter, it contributed $126.4 million (19.4%) to the total revenue.

Of the total revenue, $229.2 million came from EMEA during the last fiscal quarter, accounting for 35.2%. This represented a surprise of +8.85% as analysts had expected the region to contribute $210.56 million to the total revenue. In comparison, the region contributed $206.8 million, or 34.9%, and $217.2 million, or 33.3%, to total revenue in the previous and year-ago quarters, respectively.

Other (primarily Canada and Latin America) accounted for 6.8% of the company's total revenue during the quarter, translating to $44.5 million. Revenues from this region represented a surprise of +7.98%, with Wall Street analysts collectively expecting $41.21 million. When compared to the preceding quarter and the same quarter in the previous year, Other (primarily Canada and Latin America) contributed $45.1 million (7.6%) and $41.1 million (6.3%) to the total revenue, respectively.

Projected Revenues in Foreign Markets

For the current fiscal quarter, it is anticipated by Wall Street analysts that Bio-Rad will post revenues of $661.87 million, which reflects an increase of 1.4% the same quarter in the previous year. The revenue contributions are expected to be 20% from Asia ($132.21 million), 31.4% from EMEA ($207.87 million) and 6.3% from Other (primarily Canada and Latin America) ($41.89 million).

For the entire year, the company's total revenue is forecasted to be $2.53 billion, which is a reduction of 2% from the previous year. The revenue contributions from different regions are expected as follows: Asia will contribute 21.5% ($543.13 million), EMEA 33.7% ($853.02 million) and Other (primarily Canada and Latin America) 6.8% ($171.15 million) to the total revenue.

In Conclusion

Bio-Rad's leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.

In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.

At Zacks, we place significant importance on a company's evolving earnings outlook. This is based on empirical evidence demonstrating its strong influence on a stock's short-term price movements. Invariably, there exists a positive relationship -- an upward revision in earnings estimates is typically mirrored by a rise in the stock price.

The Zacks Rank, our proprietary stock rating mechanism, demonstrates a notable performance history confirmed through external audits. It effectively utilizes the power of earnings estimate revisions to act as a predictor of a stock's price performance in the near term.

Bio-Rad currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

A Look at Bio-Rad Laboratories' Recent Stock Price Performance

Over the past month, the stock has gained 19% versus the Zacks S&P 500 composite's 3.4% increase. The Zacks Medical sector, of which Bio-Rad is a part, has declined 0.4% over the same period. The company's shares have increased 42.4% over the past three months compared to the S&P 500's 6% increase. Over the same period, the sector has risen 10.8%

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research